Review
Medicine, General & Internal
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll, Jon Florholmen
Summary: This review discusses the use of TNF antibodies in treating IBD and the evaluation of therapeutic efficacy using current and novel biomarkers. It emphasizes the urgent need for validation and comparison studies of promising novel biomarkers to improve their value in clinical practice.
Review
Biology
Ioana Ruxandra Mihai, Alexandra Maria Burlui, Ioana Irina Rezus, Catalina Mihai, Luana Andreea Macovei, Anca Cardoneanu, Otilia Gavrilescu, Mihaela Dranga, Elena Rezus
Summary: TNF-a inhibitors have greatly improved the treatment of immune-mediated diseases, but paradoxical effects may occur, leading to the appearance or exacerbation of certain conditions. Close monitoring and timely adjustment of treatment are necessary for patients receiving TNFi therapy.
Review
Pharmacology & Pharmacy
Linshan Duan, Shuyu Cheng, Long Li, Yanling Liu, Dan Wang, Guoyan Liu
Summary: Inflammatory bowel disease (IBD) is a chronic intestinal inflammation caused by various factors, with Crohn's disease and ulcerative colitis being the two major types. Most commonly used drugs for IBD have adverse reactions and limited long-term efficacy, leading to challenges in treating patients. Research suggests that natural compounds with anti-inflammatory activities could offer potential therapeutic strategies for IBD.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: The de-escalation of biologic therapy in inflammatory bowel disease (IBD) carries risks and uncertainties and should be tailored to individual patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, General & Internal
Marcin Sochal, Jakub Fichna, Agata Gabryelska, Renata Talar-Wojnarowska, Piotr Bialasiewicz, Ewa Malecka-Wojciesko
Summary: This study evaluated serum levels of chemerin in patients with inflammatory bowel disease (IBD), finding that chemerin levels were significantly higher during exacerbation of the disease and correlated with severity of Crohn's disease (CD). Anti-TNF therapy significantly decreased chemerin levels, suggesting its potential relationship with disease activity in IBD and potential clinical utility as a monitoring tool.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Joel Thunberg, Olle Bjorkqvist, Charlotte R. H. Hedin, Anders Forss, Charlotte Soderman, Daniel Bergemalm, Ola Olen, Henrik Hjortswang, Hans Strid, Jonas F. Ludvigsson, Carl Eriksson, Jonas Halfvarson
Summary: This study analyzed the clinical outcomes of ustekinumab in patients with ulcerative colitis. The results showed that ustekinumab treatment had a high drug persistence rate and improvements in clinical, biochemical, and health-related quality of life measures among patients with ulcerative colitis.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2022)
Review
Medicine, General & Internal
Zhaobei Cai, Shu Wang, Jiannan Li
Summary: Inflammatory bowel disease (IBD) is a global disease that has attracted significant research interest. Constant research has led to a better understanding of the disease and promoted the development of conventional and novel treatments. From small molecules to cell therapy, diverse therapeutic options are emerging, offering new hope for treating IBD.
FRONTIERS IN MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Nikolaos-Panagiotis Andreou, Maria Gazouli, Ioannis E. Koutroubakis
Summary: This study investigated the association of serum antinuclear antibodies (ANA) with infliximab (IFX) and adalimumab (ADA) trough levels (TLs) and anti-drug antibodies in patients with inflammatory bowel disease (IBD) receiving IFX or ADA therapy. The results showed that ANA positivity was associated with lower TLs in IBD patients receiving anti-TNF therapy, but no significant association was found with the development of cutaneous or rheumatological manifestations.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Review
Engineering, Environmental
Han Liu, Jinru Sun, Mingkai Wang, Sicheng Wang, Jiacan Su, Can Xu
Summary: Inflammatory bowel disease (IBD) is a serious gastrointestinal disease characterized by pain, diarrhea, and bloody stools. Intestinal organoids and organoids extracellular vesicles (OEVs) have shown great potential in IBD treatment. Intestinal organoids have various applications in disease modeling, drug development, and host-microbe interactions, while OEVs have physiological effects and can participate in physiological and pathological processes. This review provides an overview of IBD and its current treatments, as well as the construction and applications of intestinal organoids and OEVs in IBD treatment. The advantages and challenges of these approaches are also discussed.
CHEMICAL ENGINEERING JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Sara Salvador-Martin, Alejandra Melgarejo-Ortuno, Luis A. Lopez-Fernandez
Summary: The use of biological drugs in pediatric inflammatory bowel disease has shown significant improvements, and predicting response to these drugs is particularly valuable in children. Clinical, biochemical, and genetic parameters can potentially predict response to biological drugs in children with IBD.
Review
Medicine, Research & Experimental
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Summary: Crohn's disease and ulcerative colitis, as chronic autoimmune diseases, are rapidly increasing in incidence in Asia. Monoclonal antibodies (mAbs) have shown promising effects in treating IBD, particularly moderate-to-severe CD and UC, by targeting inflammatory pathways. This review comprehensively summarizes the clinical reports and studies on the use of mAbs in IBD treatment in Asian countries, highlighting the current status and differences with the West.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Gastroenterology & Hepatology
Tommaso Lorenzo Parigi, Ferdinando D'Amico, Maria Abreu, Axel Dignass, Iris Dotan, Fernando Magro, Anne M. Griffiths, Vipul Jairath, Marietta Iacucci, Gerassimos J. Mantzaris, Colm O'Morain, Walter Reinisch, David B. Sachar, Dan Turner, Takayuki Yamamoto, David Rubin, Laurent Peyrin-Biroulet, Subrata Ghosh, Silvio Danese
Summary: Under the guidance of the International Organization for the Study of Inflammatory Bowel Disease, a consensus meeting was held to propose a common operative definition for difficult-to-treat IBD. Difficult-to-treat IBD is defined by the failure of biologics and advanced small molecules with at least two different mechanisms of action, or postoperative recurrence of Crohn's disease after two surgical resections in adults, or one in children. Chronic antibiotic-refractory pouchitis, complex perianal disease, and comorbid psychosocial complications that impair disease management also qualified as difficult-to-treat IBD.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Li Yang, Xiaomei Song, Yan Chen, Yue Li, Yubei Gu, Xinying Wang, Liangru Zhu, Min Zhi, Chunhui Ouyang, Hong Guo
Summary: The study found a significant difference between ideal and actual decision-making in IBD patients in China, with factors influencing ideal decision-making including income, education, illness severity, religiosity, importance of the treatment decision, employment situation, and occupation area; while factors affecting actual decision-making included age, illness severity, religiosity, employment situation, economic anxiety, concern about side effects, and importance of the treatment decision.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Pharmacology & Pharmacy
Sara Salvador-Martin, Bartosz Kaczmarczyk, Rebeca Alvarez, Victor Manuel Navas-Lopez, Carmen Gallego-Fernandez, Ana Moreno-Alvarez, Alfonso Solar-Boga, Cesar Sanchez, Mar Tolin, Marta Velasco, Rosana Munoz-Codoceo, Alejandro Rodriguez-Martinez, Concepcion A. Vayo, Ferran Bossacoma, Gemma Pujol-Muncunill, Maria J. Fobelo, Antonio Millan-Jimenez, Lorena Magallares, Eva Martinez-Ojinaga, Ines Loverdos, Francisco J. Eizaguirre, Jose A. Blanca-Garcia, Susana Clemente, Ruth Garcia-Romero, Vicente Merino-Bohorquez, Rafael Gonzalez de Caldas, Enrique Vazquez, Ana Dopazo, Maria Sanjurjo-Saez, Luis A. Lopez-Fernandez
Summary: This study identified overexpression of FCGR1A, FCGR1B, and GBP1 genes as potential pharmacogenomic markers of early response to anti-TNF agents in pediatric IBD patients.
Editorial Material
Gastroenterology & Hepatology
Nathalie Van Den Berghe, Bram Verstockt, Severine Vermeire, Debby Thomas, Paul Declerck
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Kevin L. Winthrop, Severine Vermeire, Millie D. Long, Julian Panes, Siew C. Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y. Melmed
Summary: The incidence rates of herpes zoster in patients with ulcerative colitis remained stable during 7.8 years of tofacitinib exposure. Older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor failure were identified as significant risk factors for herpes zoster.
INFLAMMATORY BOWEL DISEASES
(2023)
Letter
Gastroenterology & Hepatology
Dahham Alsoud, Bram Verstockt, Severine Vermeire
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, Research & Experimental
Walter Reinisch, Adrian Serone, Xavier Hebuterne, Tanja Kuehbacher, Maria Klopocka, Xavier Roblin, Jens Brodbeck, Kim Etchevers, Rene Galien, Ethan Grant, Chantal Tasset, Oh Kyu Yoon, Shiva Zaboli, Severine Vermeire
Summary: This study examines the relationship between endoscopic, histologic, and molecular activity in patients with Crohn's disease. The findings suggest that histologic activity should be considered when assessing inflammatory burden in CD patients.
Article
Gastroenterology & Hepatology
Silvio Danese, Marc Ferrante, Brian G. Feagan, Laurent Peyrin-Biroulet, Toshifumi Hibi, William J. Sandborn, Stefan Schreiber, Timothy Ritter, Edward V. Loftus, Gerhard Rogler, Alessandra Oortwijn, Chohee Yun, Franck-Olivier Le Brun, Jason Dinoso, Jeremy Hsieh, Severine Vermeire
Summary: This study evaluated the efficacy and sustainability of filgotinib in treating moderately to severely active ulcerative colitis (UC) patients using the Mayo Clinic Score (pMCS) and patient-reported subscores. The results showed that treatment with filgotinib improved UC symptoms within 7 days and a higher proportion of patients achieved clinical remission at weeks 10 and 58.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Pieter Sinonquel, Severine Vermeire, Frederik Maes, Raf Bisschops
Summary: This article reviews the latest developments in advanced GI endoscopy, focusing on screening, diagnosis, and surveillance of common upper and lower GI pathology. The importance of artificial intelligence in the field is emphasized, and the potential future impact of the literature is assessed.
GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sara Deleu, Kaline Arnauts, Lowie Deprez, Kathleen Machiels, Marc Ferrante, Geert R. B. Huys, Johan M. M. Thevelein, Jeroen Raes, Severine Vermeire
Summary: Short-chain fatty acids and their bacterial producers are gaining increasing attention in inflammatory bowel diseases. Acetate, although less studied compared to butyrate, shows potential in being less toxic to epithelial cells, stimulating butyrate-producing bacteria, and having anti-inflammatory and barrier-protective properties. In a study using organoid-based monolayer cultures from ulcerative colitis patients, high acetate concentrations were found to improve epithelial resistance, decrease pro-inflammatory markers, and enhance barrier gene expression. These findings suggest that acetate may offer a promising approach for managing barrier defects and inflammation in IBD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Wannee Kantasiripitak, Sebastian G. Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Severine Vermeire, Karen van Hoeve, Erwin Dreesen
Summary: The study aimed to develop a multi-model model-based software tool for guiding personalized infliximab induction treatment in pediatric inflammatory bowel disease patients. The study found that using the tool for individualized dosing improved the chances for children to achieve deep remission at 6 months.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Loris Riccardo Lopetuso, Sara Deleu, Lihi Godny, Valentina Petito, Pierluigi Puca, Federica Facciotti, Harry Sokol, Gianluca Ianiro, Luca Masucci, Maria Abreu, Iris Dotan, Samuel Paul Costello, Ailsa Hart, Tariq H. Iqbal, Sudarshan Paramsothy, Maurizio Sanguinetti, Silvio Danese, Herbert Tilg, Fabio Cominelli, Theresa T. Pizarro, Alessandro Armuzzi, Giovanni Cammarota, Antonio Gasbarrini, Severine Vermeire, Franco Scaldaferri
Summary: An international panel of experts has generated evidence-based guidelines for the evaluation and management of inflammatory bowel disease (IBD) using faecal microbiota transplantation (FMT). The guidelines provide specific statements and recommendations to promote FMT as a recognized strategy for the treatment of IBD.
Article
Gastroenterology & Hepatology
Daan Jansen, Gwen Falony, Sara Vieira-Silva, Ceren Simsek, Tine Marcelis, Clara Caenepeel, Kathleen Machiels, Jeroen Raes, Severine Vermeire, Jelle Matthijnssens
Summary: This study found that the composition of gut viruses is associated with the pathophysiology and therapeutic success of inflammatory bowel disease (IBD), identifying two distinct gut viral configurations. These findings suggest a potential clinical relevance of gut viruses in the development and treatment of IBD.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Immunology
Jeroen Geldof, Marie Truyens, Joao Sabino, Marc Ferrante, Jo Lambert, Hilde Lapeere, Tom Hillary, An Van Laethem, Kurt de Vlam, Patrick Verschueren, Elizaveta Padalko, Triana Lobaton, Severine Vermeire
Summary: The BELCOMID study confirms the benign course of COVID19 infection and vaccination in a large real-life population of patients with immune-mediated inflammatory diseases. However, the results emphasize the need for repeated vaccination and smoking cessation in IMID patients treated with immune-modulating therapies or systemic steroids during the pandemic.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
S. Haenen, B. Verstockt, M. Ferrante, S. Vermeire, J. Sabino
Summary: Crohn's disease (CD) is a chronic inflammatory bowel disease that rarely affects the lungs. However, in this case report, CD presented with pulmonary manifestations as the first sign.
ACTA GASTRO-ENTEROLOGICA BELGICA
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro
Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Biochemical Research Methods
Bryan Linggi, Jonathan Cremer, Zhongya Wang, Tanja Van Viegen, Severine Vermeire, Pavine Lefevre, Lisa M. Shackelton, Vipul Jairath, Wendy Teft, Niels Vande Casteele, Bram Verstockt
Summary: Clinical trials of novel therapies for ulcerative colitis may benefit from immune cell profiling, but implementation is limited by the necessity of timely isolation and processing of peripheral blood mononuclear cells (PBMC). The use of Becton Dickinson Vacutainer CPTTM Cell Preparation Tubes (CPTTM) allows for delayed processing of PBMC, with ideal processing within 48 hours. Delayed processing may be considered for cell types that are robust to these conditions.
JOURNAL OF IMMUNOLOGICAL METHODS
(2023)